Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin ()
Affiliation(s)
1Gastroenterology and Hepatology, Internal Medicine, Faculty of Medicine, Taiz University, Taiz, Yemen.
2Internal Medicine, Internal Medicine Department, Faculty of Medicine, Taiz University, Taiz, Yemen.
3Alfa Medical Lab, Ibb, Yemen.
ABSTRACT
Objectives: To study the effectiveness and safety of ledipasvir-sofosbuvir plus ribavirin treatment in Yemeni patient with HCV infection. Design: Prospective study of sixty-five Yemeni patients confirmed with HCV infection during the period from January 2017 to April 2018. Setting: Gastrointestinal and liver diseases specialized center in Ibb city, Yemen. Subjects: Patients with proved HCV infection by PCR. Results: We collected 65 cases with HCV infection. They were 19 (29.2%) males and 46 (70.8) females with age ranged between 18 years and 70 years and the mean age was 47.98 ± 11.90 years. sixteen (24.6%) of them had compensated liver cirrhosis and the remainder were non-cirrhotic healthy individual. The early virological response reported in 100% of cases while the sustained virological response (SVR) reported in 90.8%. The reported side effects of our patients were fatigue in (24.6%), abdominal pain in (13.8%), diarrhea in (10.8%), insomnia in (9.2%), headache in (7.7%), and nausea/vomiting in (7.7%). Conclusion: The Sofosbuvir-ledipasvir plus Ribavirin treatment was highly effective and safe for the treatment of hepatitis C patients in Yemen.
Share and Cite:
Kassim, A. , Alathwary, R. and Al-hogami, T. (2019) Response of HCV Yemeni Patients to Sofosbuvir/Ledipasvir in Combination with Ribavirin.
Open Access Library Journal,
6, 1-9. doi:
10.4236/oalib.1105507.
Cited by
No relevant information.